HCG Microdosing on TRT: Dosing Protocol, Injection Technique, and What the Evidence Says

Why TRT Suppresses Testicular Function

Exogenous testosterone shuts down the hypothalamic-pituitary-gonadal (HPG) axis fast. When the pituitary senses adequate circulating testosterone, it stops releasing luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Without LH, Leydig cells in the testes stop producing intratesticular testosterone (ITT). Without ITT and FSH, Sertoli cells cannot support spermatogenesis.

The numbers are sobering. A 2011 study in the Journal of Clinical Endocrinology and Metabolism found that intratesticular testosterone concentrations are roughly 100 times higher than serum testosterone, and that this local concentration is required for normal spermatogenesis [1]. A systematic review published in Fertility and Sterility (2013, N=1,549 men) found that TRT rendered approximately 40% of men azoospermic within 6 months and reduced sperm concentration in the remaining majority [2]. Testicular volume also declines measurably. One prospective study reported a mean 20 to 25% reduction in testicular volume after 6 to 12 months of testosterone therapy without hCG co-administration [3].

These changes are often reversible, but recovery is slow. The same Fertility and Sterility review noted median time to recovery of spermatogenesis was 6 months, with full recovery taking up to 24 months in some men [2]. For men who want to father children in the future, that lag is clinically significant.

What HCG Does and Why Microdosing Works

HCG is a glycoprotein that shares the beta-subunit structural homology with LH. It binds the LH receptor on Leydig cells with high affinity, stimulating endogenous testosterone synthesis inside the testes. When used alongside exogenous testosterone, hCG essentially bypasses the suppressed pituitary and signals the testes directly.

The traditional approach used 1,000, 2 to 000 IU of hCG two or three times per week. That bolus strategy often caused supraphysiologic hCG peaks, receptor desensitization, and excessive estradiol conversion because high ITT levels upregulate aromatase in Leydig cells [4]. Microdosing solves that problem by spreading a much smaller total weekly dose across more frequent injections, smoothing the pharmacokinetic curve and reducing estradiol spikes.

A widely cited 2005 paper by Coviello et al. in the Journal of Clinical Endocrinology and Metabolism tested hCG doses of 125, 250, and 500 IU every other day in men receiving a standard testosterone enanthate regimen. All three doses maintained intratesticular testosterone above the threshold required for spermatogenesis. The 250 IU every-other-day arm maintained ITT at 7.2 nmol/g tissue, compared to 5.8 nmol/g in the testosterone-alone arm (P<0.05), without significantly increasing serum estradiol above the testosterone-only baseline [4]. That paper is the primary pharmacokinetic anchor for today's 250 IU every-other-day and 150 to 200 IU daily protocols.

The American Urological Association's 2018 guideline on male infertility states directly: "Clinicians should offer hCG-based therapy to hypogonadal patients who wish to preserve fertility prior to and during testosterone therapy." [5]

Standard TRT Plus HCG Microdosing Protocol

Most telehealth and urology-based TRT programs that include hCG follow a two-component protocol. Testosterone cypionate (the most commonly prescribed injectable testosterone in the United States) is dosed at 100 to 200 mg per week, split into two subcutaneous or intramuscular injections. HCG is layered on top at a microdose.

The two most common hCG microdosing schedules are:

Daily dosing: 150 to 200 IU subcutaneous every morning. Total weekly dose: 1,050, 1 to 400 IU. This produces the most stable hCG serum levels and minimizes peak-trough oscillation in ITT. Men who are actively trying to conceive often use this schedule.

Every-other-day dosing: 250 to 350 IU subcutaneous on alternating days. Total weekly dose: 875, 1 to 225 IU. The Coviello et al. data specifically validated 250 IU every other day [4]. This schedule requires fewer injections and suits men who want fertility preservation without daily administration.

Monitoring while on this combined protocol should include serum LH (expected to remain suppressed, confirming hCG is carrying the signaling load), estradiol (sensitive assay, target 20, 30 pg/mL), total and free testosterone, hematocrit, and a semen analysis at 3 to 6 months if fertility is an active concern. The Endocrine Society's clinical practice guideline on male hypogonadism (2018 update) recommends measuring testosterone 3 to 6 months after initiating therapy and at least annually thereafter [6].

HealthRX Clinical Triage Framework: Choosing Your HCG Microdosing Schedule

| Patient profile | Recommended schedule | Starting dose | |---|---|---| | Active fertility attempt (trying to conceive now) | Daily | 200 IU/day | | Fertility preservation only (no immediate plans) | Every other day | 250 IU/EOD | | History of high estradiol on previous hCG | Every other day, lower dose | 150 IU/EOD | | Testicular atrophy, no fertility concern | Every other day | 250 IU/EOD |

This framework is a starting point. Individual dose adjustments are guided by estradiol levels and clinical response at the 6 to 8 week follow-up.

Intramuscular vs Subcutaneous Injection for HCG

Most clinicians now prefer subcutaneous (SubQ) delivery for hCG microdosing, and there are practical reasons behind that preference.

HCG is a water-soluble peptide hormone. Unlike oil-based testosterone esters, it does not require intramuscular (IM) injection for adequate absorption. SubQ delivery into abdominal or thigh fat produces reliable bioavailability. A pharmacokinetic comparison published in Fertility and Sterility showed that SubQ hCG produced serum hCG concentrations comparable to IM delivery, with no statistically significant difference in peak concentration or area under the curve [7]. SubQ injections are less painful, carry a lower risk of hitting a vessel, and are easier for patients to self-administer consistently.

IM delivery of hCG is still used, particularly in traditional fertility protocols where larger volumes are administered. For microdosing volumes (typically 0.05 to 0.2 mL of a reconstituted 10 to 000 IU/mL or bacteriostatic water-diluted vial), SubQ is clearly more practical.

For testosterone cypionate itself, the picture is more nuanced. A 2017 study in the Journal of Urology (N=37 hypogonadal men) found that SubQ testosterone cypionate at 50 to 60 mg twice weekly produced trough testosterone levels comparable to standard IM weekly dosing, with similar hematocrit profiles and without injection-site adverse events beyond mild transient erythema [8]. Many TRT-plus-hCG programs now use SubQ for both components, simplifying the patient's injection routine to a single technique.

Step-by-Step Subcutaneous Injection Technique for HCG Microdosing

Consistent technique matters more than most patients realize. Variation in injection depth and site rotation is the most common reason for erratic serum levels.

Equipment: Use a 29, 31 gauge, 5/16-inch (8 mm) insulin syringe for SubQ hCG microdosing. The small gauge minimizes discomfort and the short needle length is appropriate for subcutaneous depth in abdominal tissue.

Site selection and rotation: The lower abdomen (at least 2 inches from the navel) and the anterior thigh are the two primary sites. Rotate within each site, spacing injections at least 1 cm apart from the previous one. Rotating prevents lipodystrophy and local desensitization of subcutaneous receptors.

Preparation: Wash hands for 20 seconds with soap. Wipe the vial stopper and the injection site with a fresh alcohol swab. Allow both to air-dry for 10 seconds before proceeding. Wet alcohol on the skin stings and can carry surface bacteria into the tissue.

Drawing the dose: Insert the syringe needle into the vial, invert, and draw 10 to 20% more than the target volume. Tap the barrel and push the plunger to expel air bubbles back into the vial, then dial back to the exact target volume.

Injection: Pinch a fold of skin approximately 1 inch wide between thumb and forefinger. Insert the needle at a 45-degree angle (or 90 degrees if abdominal tissue is substantial). Release the skin fold once the needle is seated. Inject the dose slowly, over 5, 10 seconds. Withdraw at the same angle of entry. Apply light pressure with a dry gauze pad for 10, 15 seconds.

Storage: Reconstituted hCG degrades quickly at room temperature. Store mixed vials at 2, 8°C (refrigerator temperature) and use within 30 days. Lyophilized (powder) vials are stable at room temperature until reconstituted.

HCG Microdosing and Estradiol: Managing the Aromatase Effect

One reason some physicians hesitated to add hCG to TRT was estradiol elevation. Leydig cells express aromatase, and higher ITT from hCG stimulation can increase local estradiol production.

At microdosing levels, this effect is small but measurable. The Coviello 2005 study found that the 500 IU every-other-day arm raised serum estradiol by approximately 14% compared to the testosterone-only arm, while the 250 IU and 125 IU arms showed increases of 8% and 4%, respectively [4]. In men whose estradiol is already at the upper end of range on TRT alone, even an 8% rise can push them above 35, 40 pg/mL, the threshold where gynecomastia risk and water retention symptoms tend to emerge.

The practical response is to check a sensitive estradiol assay (LC-MS/MS method, not the standard immunoassay) at baseline and at 6 to 8 weeks after starting hCG. If estradiol exceeds 35 pg/mL with symptoms, the options are reducing the hCG dose by 25 to 30%, reducing the testosterone dose slightly, or adding a low-dose aromatase inhibitor such as anastrozole 0.25 to 0.5 mg twice weekly. Routine aromatase inhibitor use without documented elevated estradiol is not recommended by either the Endocrine Society or the AUA, as over-suppression of estradiol causes bone density loss, mood disruption, and impaired lipid metabolism [6].

Fertility Outcomes: What the Data Actually Show

Men who use hCG alongside TRT consistently show better semen parameters than those on testosterone alone.

A prospective study published in Fertility and Sterility followed 26 men on testosterone with concurrent hCG (500 IU three times weekly) and compared them to 20 men on testosterone alone [9]. After 12 months, 96% of the hCG group maintained a sperm concentration above 20 million/mL, compared to 20% in the testosterone-only group. Mean testicular volume was 16.8 mL in the hCG group versus 10.4 mL in the testosterone-only group (P<0.001) [9].

Microdosing data are less abundant than bolus-dose data, but the pharmacokinetic evidence from Coviello et al. supports equivalent ITT maintenance at 250 IU every other day relative to the older 500 IU three-times-weekly schedule, with a lower total weekly dose (875 IU vs. 1 to 500 IU) and a more favorable estradiol profile [4].

For men who want to stop TRT and restore natural testosterone production, hCG monotherapy (without exogenous testosterone) is sometimes used as a transitional step. A small pilot trial (N=14) in the Journal of Urology showed that hCG at 3 to 000 IU every other day for 3 months restored serum testosterone to above 300 ng/dL in 11 of 14 men after TRT cessation, with mean serum testosterone rising from 164 ng/dL at baseline to 481 ng/dL at 12 weeks [10]. This is a distinct use case from microdosing but shares the same receptor mechanism.

Compounded vs. FDA-Approved HCG: A Regulatory Note

The FDA approved Pregnyl and Novarel (both choriogonadotropin alfa injection) for specific indications including hypogonadotropic hypogonadism in males [11]. In 2020, the FDA removed compounded hCG from its list of bulk substances eligible for compounding under Section 503A, creating a period of access uncertainty. Compounded hCG prepared by 503B outsourcing facilities for office use by licensed practitioners remained permissible under different regulatory provisions.

As of this writing, men receiving hCG microdosing through a licensed telehealth provider may receive either brand-name choriogonadotropin alfa or a preparation from an FDA-registered 503B outsourcing facility. Patients should confirm their pharmacy's regulatory status. Buying hCG from unverified online sources carries risks of incorrect concentration, sterility failures, and counterfeit product. The FDA MedWatch database lists adverse event reports associated with non-pharmacy-grade peptide injections [12].

Who Should Not Use HCG

HCG is contraindicated in men with androgen-sensitive prostate cancer, as it stimulates intratesticular testosterone that may support tumor growth. Men with a history of hormone-sensitive malignancy should discuss this with a urologist before any hCG protocol.

HCG may also worsen polycythemia because higher ITT can augment the erythropoietic effect of exogenous testosterone. Monitor hematocrit at 3-month intervals; a hematocrit above 54% warrants dose reduction or therapeutic phlebotomy per Endocrine Society guidance [6].

Men with a history of prior hCG hypersensitivity reactions, testicular tumors, or precocious puberty (in pediatric contexts) should not receive hCG.